Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SQZ-AAC-HPV phase 1 study in HPV16-positive advanced solid tumors
NL-OMON50875Phase 1Withdrawn
- Sponsor
- SQZ Biotechnologies
- Start
- Jul 2021
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Tissue Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of SQZ-AAC-HPV in Nonhematologic neoplasms, Cervical Cancer (CC), head and neck cancer (HNC) and 1 more (4 arms), sponsored by SQZ Biotechnologies. Primary endpoints: Safety and tolerability, Recommended phase 2 dose for monotherapy and 1 more. Planned start Jul 2021; status: withdrawn.
02
Drugs
SQZ-AAC-HPV
03
Conditions
Nonhematologic neoplasmsCervical Cancer (CC)head and neck cancer (HNC)anal cancer
Beyond the preview
Go deeper on NL-OMON50875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50875.